Nureca Ltd.

₹406.7 34.5 | 9.3%

WEBSITE BSE:543264 NSE : NURECA 15 Jan, 16:01

Market Cap ₹407 Cr.

Stock P/E -226.7

P/B 2.1

Current Price ₹406.7

Book Value ₹ 193.4

Face Value 10

52W High ₹424

Dividend Yield 0%

52W Low ₹ 240.9

Edit Ratio

Nureca Ltd. Research see more...

Overview Inc. Year: 2016Industry: Medical Equipment/Supplies/Accessories

Nureca Limited, a B2C agency, engages in the domestic healthcare and well-being products commercial enterprise in India. It gives chronic disease merchandise, inclusive of nebulizers, blood pressure video display units, finger pulse oximeter, glucose meter, and thermometer; orthopaedic products, which includes massagers, ache monitors, posture correctors, and rehabilitation products; and humidifiers and steamers, non-public scales, yoga and exercising, health monitoring, and dental and personal care products. The organisation also provides mother and toddler care products comprising baby feeding, carry cots, infant skincare, and bottle heaters and steamers; nutritional supplements and weight control merchandise; and ECG, health tracker, and smart weighing scale merchandise. Nureca Ltd offers its merchandise underneath Dr Trust, Dr Physio, and Trumom brands. The enterprise sells its products via third party e-trade players, vendors, and retailers; and through its website, drtrust.In. Nureca Ltd was founded in 2016 and is primarily based in Chandigarh, India.

Nureca Ltd. Share Price

New

Volume

Price

Price: NSE50 DMA200 DMAVolume

Quarterly Price

Quarterly Monthly

Show Value Show %

Peer Comparison

Nureca Ltd. Quarterly Results

#(Fig in Cr.)
Net Sales
Other Income
Total Income
Total Expenditure
Operating Profit
Interest
Depreciation
Exceptional Income / Expenses
Profit Before Tax
Provision for Tax
Profit After Tax
Adjustments
Profit After Adjustments
Adjusted Earnings Per Share

Nureca Ltd. Profit & Loss

#(Fig in Cr.)	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Net Sales	1	1	99	213	256	112	95
Other Income	0	0	0	3	8	7	11
Total Income	1	1	99	216	263	119	105
Total Expenditure	1	1	90	152	200	127	106
Operating Profit	0	0	10	64	63	-8	-1
Interest	0	0	1	2	1	0	0
Depreciation	0	0	0	0	1	2	2
Exceptional Income / Expenses	0	0	0	0	0	0	0
Profit Before Tax	0	0	9	62	61	-11	-3
Provision for Tax	0	0	2	16	16	-3	-1
Profit After Tax	0	0	6	47	45	-8	-2
Adjustments	0	0	0	0	0	0	0
Profit After Adjustments	0	0	6	47	45	-8	-2
Adjusted Earnings Per Share	2.2	3	915.7	46.5	45.3	-8.4	-2.4

Growth Rates

#	1 Year	3 Year	5 Year	10 Year
Sales CAGR	-15%	-24%	149%	0%
Operating Profit CAGR	0%	NAN%	0%	0%
PAT CAGR	0%	NAN%	0%	0%

#	1 Year	3 Year	5 Year	10 Year
Share Price CAGR	-2%	-40%	NA%	NA%
ROE Average	-1%	6%	33%	42%
ROCE Average	-1%	9%	34%	52%

Nureca Ltd. Balance Sheet

#(Fig in Cr.)	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Shareholder's Funds	0	15	163	204	195	193
Minority's Interest	0	0	0	0	0	0
Borrowings	0	9	1	0	0	0
Other Non-Current Liabilities	0	0	2	4	0	-2
Total Current Liabilities	1	9	34	45	9	9
Total Liabilities	1	34	200	252	204	199
Fixed Assets	0	1	3	10	8	6
Other Non-Current Assets	0	0	1	4	12	4
Total Current Assets	1	33	196	239	184	189
Total Assets	1	34	200	252	204	199

Nureca Ltd. Cash Flow

#(Fig in Cr.)	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Opening Cash & Cash Equivalents	0	0	0	17	8	0
Cash Flow from Operating Activities	0	-8	35	2	12	-3
Cash Flow from Investing Activities	-0	-0	-110	-3	-18	18
Cash Flow from Financing Activities	0	8	92	-7	-2	-1
Net Cash Inflow / Outflow	0	-0	17	-9	-8	14
Closing Cash & Cash Equivalent	0	0	17	8	0	14

Nureca Ltd. Ratios

#	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Earnings Per Share (Rs)	2.23	2.96	915.71	46.53	45.31	-8.42	-2.44
CEPS(Rs)	2.23	3.28	969.14	46.94	46.74	-6.12	-0.2
DPS(Rs)	0	0	0	2	3	0	0
Book NAV/Share(Rs)	3.27	6.38	1995.71	163.29	203.74	195.26	192.86
Core EBITDA Margin(%)	4.04	4.24	9.39	27.44	20.65	-13.14	-10.87
EBIT Margin(%)	4.04	4.28	9.08	28.51	22.97	-8.98	-2.74
Pre Tax Margin(%)	3.58	3.93	8.34	27.8	22.7	-9.35	-3.19
PAT Margin (%)	2.66	2.85	6.2	20.7	16.77	-7.19	-2.38
Cash Profit Margin (%)	2.66	3.15	6.56	20.88	17.3	-5.22	-0.2
ROA(%)	4.66	2.56	36.51	39.73	20.01	-3.69	-1.21
ROE(%)	68.36	61.47	91.48	52.5	24.69	-4.22	-1.26
ROCE(%)	103.85	92.41	76	67.74	33.61	-5.26	-1.45
Receivable days	87.04	67.59	22.99	10.65	2.09	11.12	10.82
Inventory Days	80.09	241.47	30.46	43.19	67.52	149.53	109.58
Payable days	231.06	528.63	19.96	26.84	18.52	22.71	26.81
PER(x)	0	0	0	12.94	30.07	0	0
Price/Book(x)	0	0	0	3.69	6.69	1.54	1.32
Dividend Yield(%)	0	0	0	0.33	0.22	0	0
EV/Net Sales(x)	-0.04	-0.1	0.1	2.24	5.01	2.05	2.23
EV/Core EBITDA(x)	-1.09	-2.22	0.99	7.39	20.15	-27.9	-370.99
Net Sales Growth(%)	0	23.85	0	114.56	19.79	-56.21	-15.53
EBIT Growth(%)	0	31.28	0	582.32	-3.17	-116.96	73.31
PAT Growth(%)	0	32.66	0	625.96	-2.63	-118.59	71
EPS Growth(%)	0	32.66	0	-94.92	-2.63	-118.59	71
Debt/Equity(x)	0	0	0.69	0.01	0.01	0	0
Current Ratio(x)	1.07	0.99	3.46	5.78	5.29	21.35	21.58
Quick Ratio(x)	0.65	0.31	1.72	4.69	3.89	17.54	18.3
Interest Cover(x)	8.81	12.32	12.2	40.13	84.9	-24.42	-6.11
Total Debt/Mcap(x)	0	0	0	0	0	0	0

Nureca Ltd. Shareholding Pattern

#	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024
Promoter	70	62.98	62.98	62.98	63.24	63.24	63.24	63.24	63.77	64.06
FII	1.67	0.1	0.1	0.1	0.1	0.07	0.07	0.07	0.69	0.36
DII	0.55	0	0	0	0	0	0	0	0	0
Public	27.77	36.91	36.91	36.91	36.66	36.69	36.69	36.69	35.53	35.58
Others	0	0	0	0	0	0	0	0	0	0
Total	100	100	100	100	100	100	100	100	100	100

#	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024
Promoter	0.7	0.63	0.63	0.63	0.63	0.63	0.63	0.63	0.64	0.64
FII	0.02	0	0	0	0	0	0	0	0.01	0
DII	0.01	0	0	0	0	0	0	0	0	0
Public	0.28	0.37	0.37	0.37	0.37	0.37	0.37	0.37	0.36	0.36
Others	0	0	0	0	0	0	0	0	0	0
Total	1	1	1	1	1	1	1	1	1	1

Pros

Company is almost debt free.

Cons

Company has a low return on equity of 6% over the last 3 years.
Debtor days have increased from 22.71 to 26.81days.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.